中国药物警戒 ›› 2026, Vol. 23 ›› Issue (6): 677-680.
DOI: 10.19803/j.1672-8629.20250557

• 安全与合理用药 • 上一篇    下一篇

243例奥氮平不良反应报告分析

潘艳娟, 岳珂欣, 刘伟杰, 王领军, 王传升*   

  1. 河南医药大学第二附属医院药学部,河南 新乡 453000
  • 收稿日期:2025-08-15 出版日期:2026-06-15 发布日期:2026-06-18
  • 通讯作者: *王传升,男,博士,教授·硕导,成瘾医学与精神药理学。E-mail: chuansonwang@126.com
  • 作者简介:潘艳娟,女,硕士,副主任药师,精神药理学。
  • 基金资助:
    “聚火优才”全国药学服务科研项目（CMEAPC2023026）

243 Reports of Adverse Drug Reactions Associated with Olanzapine

PAN Yanjuan, YUE Kexin, LIU Weijie, WANG Lingjun, WANG Chuansheng*   

  1. Department of Pharmacy, the Second Affiliated Hospital of Henan Medical University, Xinxiang Henan 453000, China
  • Received:2025-08-15 Online:2026-06-15 Published:2026-06-18

PDF (PC)

11

摘要： 目的 探讨奥氮平药品不良反应（ADR）发生的一般规律和特点,为临床合理用药提供参考。方法 收集2021年1月1日至2025年12月31日河南医药大学第二附属医院药品不良反应自发呈报系统数据库中奥氮平ADR报告,对报告信息、患者人口学特征、用药情况、累及系统-器官分布及临床表现等进行分析。结果 共纳入奥氮平ADR报告243例,新的/严重的ADR占32.10%（78/243）;ADR累及系统-器官依次为神经系统、肝胆系统、心血管系统、血液系统和胃肠系统,分别占37.45%、15.64%、15.64%、11.52%和5.76%。结论 奥氮平ADR可累及多个系统-器官,其中神经系统损害最常见。大部分不良反应发生于5、10 mg·d-1常规剂量下。奥氮平存在用药初期即可致转氨酶显著升高的特点,且女性患者更易发生血液系统损害。新的/严重的ADR占比32.10%,提示临床需持续加强奥氮平用药安全监测,重点关注肝功能、血常规相关指标,以保障合理用药。

关键词: 奥氮平, 血液系统损害, 肝胆系统损害, 心血管系统损害, 神经系统损害, 药品不良反应

Abstract: Objective To investigate the patterns of adverse drug reactions (ADRs) associated with olanzapine, and to provide a reference for rational clinical drug use. Methods ADR reports related to olanzapine and collected in 2021-2025 were retrieved from the spontaneous reporting system database of The Second Affiliated Hospital of Henan Medical University. The basic data, demographics of patients, medications, system-organ classes involved and clinical manifestations were analyzed. Results A total of 243 reports on ADRs of olanzapine were included, 32.10% of which (78/243) were classified as “new/serious.” The most common systems involved were the nervous system (37.45%), hepatobiliary system (15.64%), cardiovascular system (15.64%), hematological system (11.52%), and gastrointestinal system (5.76%). Conclusion The ADRs of olanzapine can involve multiple systems and organs. Damage to the nervous system is the most common. Most of these ADRs occur at conventional doses of 5 mg·d-1 and 10 mg·d-1. Olanzapine is likely to induce a marked increase in transaminase levels in early treatment, and female patients are more susceptible to hematologic system damage. The safety of olanzapine needs to be monitored in clinical practice, especially in terms of liver function and routine blood tests.

Key words: Olanzapine, Hematological System Damage, Hepatobiliary System Damage, Cardiovascular System Damage, Nervous System Damage, Adverse Drug Reactions

中图分类号: